Abstract: A container suspension and release system provides at least one ejector assembly having a carry position and a deployed position. The ejector assembly includes an actuator configured to extend ejector assembly from the carry position to the deployed position, and a retention assembly. The retention assembly employs a bracket attached to the actuator and a fixed sway brace extending from the bracket. A left retention arm is pivotally attached to the bracket and a right retention arm is pivotally attached to the bracket, with the left and right retention arms configured to rotate in opposite directions. A rotation activation mechanism is provided to rotate the left and right retention arms in the deployed position. An energy source connected to the actuator to provides energy to actuate the at least one ejector assembly.

Abstract: Methods are disclosed for producing populations of cardiomyocytes from pluripotent stem cells. Populations may be enriched for either atrial or ventricular cardiomyocytes and the resulting ventricular population may be essentially free of pacemaker cells. The method includes incubating pluripotent stem cells in a suitable medium with a BMP component, and an activin component, the amounts of activin may be varied to enrich for either atrial or ventricular cardiomyocytes. The enriched populations, as well as methods of using the same to treat patients in need of cardiac repair are disclosed.

Abstract: Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.

Abstract: Provided are methods for making yolk sac like hematopoietic progenitors by specifying a KDR+CD235a/b+ mesoderm cells capable of giving rise to T lymphoid lineage cells or cells differentiated therefrom. The method involves contacting pluripotent stem cells (PSCs) with a mesoderm specifying culture composition comprising a BMPR1/R2 agonist, an FGF receptor agonist and an activin receptor agonist to produce a KDR+CD235a/b+ mesoderm cells; and optionally isolating the KDR+CD235a/b+ mesoderm cells.

Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.

Abstract: This disclosure describes vascular endothelial cells (VECs) and liver sinusoidal endothelial cells (LSECs), and methods and compositions for producing such cells.

Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.

Abstract: Container retention and release apparatus are disclosed. An example container retention and release apparatus includes an actuator and a swaybrace and retention assembly pivotally coupled to the actuator. The swaybrace and retention assembly is to pivot relative to the actuator between a first position to retain a container and a second position to release the container. The swaybrace and retention assembly includes a swaybrace arm having a receptacle to engage a post of a container. The swaybrace arm to pivot between the first position to cause the receptacle to engage the post of the container to retain the container and the second position to cause the receptacle to disengage the post to release the container.

Abstract: A container suspension and release system provides at least one ejector assembly having a carry position and a deployed position. The ejector assembly includes an actuator configured to extend ejector assembly from the carry position to the deployed position, and a retention assembly. The retention assembly employs a bracket attached to the actuator and a fixed sway brace extending from the bracket. A left retention arm is pivotally attached to the bracket and a right retention arm is pivotally attached to the bracket, with the left and right retention arms configured to rotate in opposite directions. A rotation activation mechanism is provided to rotate the left and right retention arms in the deployed position. An energy source connected to the actuator to provides energy to actuate the at least one ejector assembly.

Abstract: A container retention and release apparatus includes an actuator a swaybrace and retention assembly pivotally coupled to the actuator. The swaybrace and retention assembly pivot relative to the actuator between a first position to retain a container and a second position to release the container.

Abstract: Provided herein are methods of making and using a number of different types of liver cells.

Abstract: Container retention and release apparatus are disclosed. An example container retention and release apparatus includes an actuator, a swaybrace coupled to the actuator, and a clamp pivotally coupled to the swaybrace. The clamp pivots between a clamping position to retain a container and a release position to release a container.

Abstract: Disclosed herein are methods of producing a population of venous angioblast cells from stem cells using a venous angioblast inducing media and optionally isolating a CD34+ population from the cell population comprising the venous angioblast cells, for example using a CD34 affinity reagent, CD31 affinity reagent and/or CD144 affinity reagent, optionally with or without a CD73 affinity reagent as well as methods of further differentiating the venous angioblasts in vitro to produce SEC-LCs and/or in vivo to produce SECs. Uses of the cells and compositions comprising the cells are also described.

Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.

Abstract: Methods and products for obtaining cardiovascular lineage cells from hPSCs. The method comprises one or more of the following steps: (a) contacting BMP component primed hPSCs with a cardiovascular mesoderm programming cocktail and culturing the contacted hPSCs for a period of time to generate a KDR+ and PDGFRalpha+ cardiovascular mesoderm cell population; (b) contacting the cardiovascular mesoderm cell population with a cardiovascular progenitor specification cocktail and culturing the contacted cardiovascular mesoderm cell population for a period of time to generate a NKX2-5+ or WT1+ cardiovascular progenitor cell population; and (c) contacting the cardiovascular progenitor cell population with a maturation cocktail and culturing the contacted cardiovascular progenitor population for a period of time to produce a cardiovascular population optionally cardiomyocyte lineage cells expressing cardiac troponin T (cTnT) and/or SIRPA and/or epicardial lineage cells expressing WT1.

Abstract: Container retention and release apparatus are disclosed. An example container retention and release apparatus includes an actuator and a swaybrace and retention assembly pivotally coupled to the actuator. The swaybrace and retention assembly is to pivot relative to the actuator between a first position to retain a container and a second position to release the container. The swaybrace and retention assembly includes a swaybrace arm having a receptacle to engage a post of a container. The swaybrace arm to pivot between the first position to cause the receptacle to engage the post of the container to retain the container and the second position to cause the receptacle to disengage the post to release the container.

Abstract: Container retention and release apparatus are disclosed. An example container retention and release apparatus includes a swaybrace to engage an exterior surface of a container. A latch is to attach to an internal receptacle of the container to retain the container. The latch is movable between a latched position to retain the container and an unlatched position to release the container. A drive is to move the latch between the latched position and the unlatched position.

Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.

Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR? primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; ?to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.

Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.